Species |
Human |
Protein Construction |
FGF-9 (Met1-Ser208) Accession # P31371 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
ED50 < 2.0 ng/ml , measured by a cell proliferation assay using 3T3 cells, corresponding to a specific activity of > 5.0× 105 units/mg. |
Expression System |
E. coli |
Apparent Molecular Weight |
~23.4 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
ED₅₀ < 2.0 ng/ml , measured by a cell proliferation assay using 3T3 cells, corresponding to a specific activity of >5.0× 105 units/mg.
Target Background |
Fibroblast Growth Factor-9 (FGF-9) is a heparin binding growth factor that belongs to the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF-9 was isolated as a secreted factor that exhibits a growth-stimulating effect on cultured glial cells. In nervous system, this protein is produced mainly by neurons and may be important for glial cell development. |
Synonyms |
Fibroblast Growth Factor-9; FGF9; GAF; Glia-activating factor; HBGF-9 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.